- By Shivangi Sharma
- Mon, 17 Nov 2025 11:27 PM (IST)
- Source:JND
China’s fast-growing biotech sector is once again drawing global attention after Lonvi Biosciences claimed it has developed a longevity pill capable of extending human life to as long as 150 years. The bold assertion, reported by The New York Times, has triggered waves of excitement and caution across scientific and medical communities worldwide.
At the heart of Lonvi’s breakthrough is procyanidin C1 (PCC1), a compound derived from grape seed extract. Earlier research conducted in Shanghai linked PCC1 to extended lifespans in rodents. Lonvi’s scientists say their tablet formulation concentrates this molecule to specifically target “zombie cells”, aged cells that stop dividing but continue to promote inflammation and age-related diseases.
According to the company, laboratory mice given the formulation lived 9.4 per cent longer overall, and remarkably, 64.2 per cent longer from the first day of treatment. Lonvi claims the compound destroys senescent cells while sparing healthy tissue, thereby supporting cellular function and potentially delaying chronic illnesses associated with ageing.
“This is not just another pill. This is the Holy Grail,” said CEO Ip Zhu, as quoted in Diario Popular. He believes that when paired with a healthy lifestyle and proper medical care, the capsule could enable humans to routinely live past 100, and even reach 120 or beyond.
ALSO READ: Bangladesh On Edge As ICT Pronounces Verdict Against Sheikh Hasina: Inside Five-Count Charge Sheet
China’s New Push Into Longevity Science
The company’s ambition mirrors a broader national trend. China has quietly elevated ageing research to the same strategic tier as artificial intelligence and advanced biotechnology. Reports suggest President Xi Jinping has personally discussed longevity projects with Russian President Vladimir Putin, who has speculated that advances in organ transplants could bring humanity closer to “immortality.”
Just ten years ago, anti-ageing science in China was viewed as fringe. Today, it is a booming sector attracting major investment. “Nobody in China used to talk about longevity, only rich Americans,” said Gan Yu, co-founder of Shanghai-based Time Pie, a startup dedicated to extending human life. “Now, many Chinese are interested and have the money to extend their lives.”
Hope Meets Skepticism
Despite the enthusiasm, experts urge caution. So far, all evidence of Lonvi’s pill is limited to animal studies, which often fail to translate directly into human outcomes. The longevity field is also notorious for bold claims that collapse under rigorous clinical testing. Scientists emphasise that extending the mouse lifespan does not necessarily mean humans can reach 150 years.